{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T08:58:42Z","timestamp":1793437122799,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T00:00:00Z","timestamp":1559520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T00:00:00Z","timestamp":1559520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Division of Periodontics, Columbia University College of Dental Medicine &amp; French Ministry of Higher Education and Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The receptor for advanced glycation endproducts (RAGE) is critically involved in the pathobiology of chronic inflammatory diseases. Soluble forms of RAGE have been proposed as biomarkers of severity in inflammatory and metabolic conditions, and in monitoring therapeutic responses. The aim of the present study was to determine circulating levels of the soluble forms of RAGE in periodontitis and to evaluate the expression of cell-bound, full-length RAGE and its antagonist AGER1 locally, in gingival tissues. Periodontitis patients and periodontally healthy, sex- and age-matched controls (50 per group) were included. Serum levels of total soluble RAGE and cleaved RAGE (cRAGE) were significantly lower in periodontitis patients. Levels of the endogenous secretory esRAGE were similar in the two groups. cRAGE remained significantly lower in the periodontitis group following multiple adjustments, and had a statistically significant inverse correlation with body mass index and all periodontal parameters. In periodontitis patients, gene expression of full-length RAGE and of AGER1 were significantly higher in periodontitis-affected gingival tissues compared to healthy gingiva. Soluble forms of RAGE, particularly cRAGE, may serve as biomarkers for the presence and severity\/extent of periodontitis, and may be implicated in its pathogenesis and its role as a systemic inflammatory stressor.<\/jats:p>","DOI":"10.1038\/s41598-019-44608-2","type":"journal-article","created":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T10:22:43Z","timestamp":1559557363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Soluble Forms of the Receptor for Advanced Glycation Endproducts (RAGE) in Periodontitis"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7180-1866","authenticated-orcid":false,"given":"Laurent","family":"Detzen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panos N.","family":"Papapanou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanthia","family":"Lalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,3]]},"reference":[{"key":"44608_CR1","doi-asserted-by":"crossref","first-page":"14998","DOI":"10.1016\/S0021-9258(18)42138-2","volume":"267","author":"M Neeper","year":"1992","unstructured":"Neeper, M. et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267, 14998\u201315004 (1992).","journal-title":"J Biol Chem"},{"key":"44608_CR2","doi-asserted-by":"publisher","first-page":"31740","DOI":"10.1074\/jbc.274.44.31740","volume":"274","author":"T Kislinger","year":"1999","unstructured":"Kislinger, T. et al. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274, 31740\u201331749 (1999).","journal-title":"J Biol Chem"},{"key":"44608_CR3","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/35012626","volume":"405","author":"A Taguchi","year":"2000","unstructured":"Taguchi, A. et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405, 354\u2013360, https:\/\/doi.org\/10.1038\/35012626 (2000).","journal-title":"Nature"},{"key":"44608_CR4","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0092-8674(00)80801-6","volume":"97","author":"MA Hofmann","year":"1999","unstructured":"Hofmann, M. A. et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100\/calgranulin polypeptides. Cell 97, 889\u2013901 (1999).","journal-title":"Cell"},{"key":"44608_CR5","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/382685a0","volume":"382","author":"SD Yan","year":"1996","unstructured":"Yan, S. D. et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer\u2019s disease. Nature 382, 685\u2013691, https:\/\/doi.org\/10.1038\/382685a0 (1996).","journal-title":"Nature"},{"key":"44608_CR6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.vph.2012.06.004","volume":"57","author":"R Ramasamy","year":"2012","unstructured":"Ramasamy, R., Yan, S. F. & Schmidt, A. M. The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes. Vascul Pharmacol 57, 160\u2013167, https:\/\/doi.org\/10.1016\/j.vph.2012.06.004 (2012).","journal-title":"Vascul Pharmacol"},{"key":"44608_CR7","doi-asserted-by":"publisher","first-page":"E685","DOI":"10.1152\/ajpendo.2001.280.5.E685","volume":"280","author":"MP Wautier","year":"2001","unstructured":"Wautier, M. P. et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280, E685\u2013694 (2001).","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"44608_CR8","doi-asserted-by":"publisher","first-page":"19891","DOI":"10.3390\/ijms141019891","volume":"14","author":"G Daffu","year":"2013","unstructured":"Daffu, G. et al. Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond. Int J Mol Sci 14, 19891\u201319910, https:\/\/doi.org\/10.3390\/ijms141019891 (2013).","journal-title":"Int J Mol Sci"},{"key":"44608_CR9","first-page":"1699","volume":"143","author":"J Brett","year":"1993","unstructured":"Brett, J. et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143, 1699\u20131712 (1993).","journal-title":"Am J Pathol"},{"key":"44608_CR10","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1172\/JCI116442","volume":"91","author":"AM Schmidt","year":"1993","unstructured":"Schmidt, A. M. et al. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest 91, 2155\u20132168, https:\/\/doi.org\/10.1172\/JCI116442 (1993).","journal-title":"J Clin Invest"},{"key":"44608_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3389\/fgene.2017.00187","volume":"8","author":"LM Senatus","year":"2017","unstructured":"Senatus, L. M. & Schmidt, A. M. The AGE-RAGE Axis: Implications for Age-Associated Arterial Diseases. Front Genet 8, 187, https:\/\/doi.org\/10.3389\/fgene.2017.00187 (2017).","journal-title":"Front Genet"},{"key":"44608_CR12","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1517\/14728222.2016.1111873","volume":"20","author":"R Ramasamy","year":"2016","unstructured":"Ramasamy, R., Shekhtman, A. & Schmidt, A. M. The multiple faces of RAGE\u2013opportunities for therapeutic intervention in aging and chronic disease. Expert Opin Ther Targets 20, 431\u2013446, https:\/\/doi.org\/10.1517\/14728222.2016.1111873 (2016).","journal-title":"Expert Opin Ther Targets"},{"key":"44608_CR13","doi-asserted-by":"publisher","first-page":"403460","DOI":"10.1155\/2013\/403460","volume":"2013","author":"YK Chuah","year":"2013","unstructured":"Chuah, Y. K., Basir, R., Talib, H., Tie, T. H. & Nordin, N. Receptor for advanced glycation end products and its involvement in inflammatory diseases. Int J Inflam 2013, 403460, https:\/\/doi.org\/10.1155\/2013\/403460 (2013).","journal-title":"Int J Inflam"},{"key":"44608_CR14","doi-asserted-by":"publisher","unstructured":"Derk, J., MacLean, M., Juranek, J. & Schmidt, A. M. The Receptor for Advanced Glycation Endproducts (RAGE) and Mediation of Inflammatory Neurodegeneration. J Alzheimers Dis Parkinsonism 8, https:\/\/doi.org\/10.4172\/2161-0460.1000421 (2018).","DOI":"10.4172\/2161-0460.1000421"},{"key":"44608_CR15","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/nrendo.2011.106","volume":"7","author":"E Lalla","year":"2011","unstructured":"Lalla, E. & Papapanou, P. N. Diabetes mellitus and periodontitis: a tale of two common interrelated diseases. Nat Rev Endocrinol 7, 738\u2013748, https:\/\/doi.org\/10.1038\/nrendo.2011.106 (2011).","journal-title":"Nat Rev Endocrinol"},{"key":"44608_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vph.2015.06.011","volume":"72","author":"AM Schmidt","year":"2015","unstructured":"Schmidt, A. M. Soluble RAGEs - Prospects for treating & tracking metabolic and inflammatory disease. Vascul Pharmacol 72, 1\u20138, https:\/\/doi.org\/10.1016\/j.vph.2015.06.011 (2015).","journal-title":"Vascul Pharmacol"},{"key":"44608_CR17","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1096\/fj.08-109033","volume":"22","author":"A Raucci","year":"2008","unstructured":"Raucci, A. et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 22, 3716\u20133727, https:\/\/doi.org\/10.1096\/fj.08-109033 (2008).","journal-title":"FASEB J"},{"key":"44608_CR18","doi-asserted-by":"publisher","first-page":"35507","DOI":"10.1074\/jbc.M806948200","volume":"283","author":"L Zhang","year":"2008","unstructured":"Zhang, L. et al. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem 283, 35507\u201335516, https:\/\/doi.org\/10.1074\/jbc.M806948200 (2008).","journal-title":"J Biol Chem"},{"key":"44608_CR19","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1096\/fj.07-9909com","volume":"22","author":"BI Hudson","year":"2008","unstructured":"Hudson, B. I. et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J 22, 1572\u20131580, https:\/\/doi.org\/10.1096\/fj.07-9909com (2008).","journal-title":"FASEB J"},{"key":"44608_CR20","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1042\/bj20021371","volume":"370","author":"H Yonekura","year":"2003","unstructured":"Yonekura, H. et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370, 1097\u20131109, https:\/\/doi.org\/10.1042\/bj20021371 (2003).","journal-title":"Biochem J"},{"key":"44608_CR21","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1093\/rheumatology\/kep199","volume":"48","author":"H Maillard-Lefebvre","year":"2009","unstructured":"Maillard-Lefebvre, H. et al. Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology (Oxford) 48, 1190\u20131196, https:\/\/doi.org\/10.1093\/rheumatology\/kep199 (2009).","journal-title":"Rheumatology (Oxford)"},{"key":"44608_CR22","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.bcp.2010.01.013","volume":"79","author":"SF Yan","year":"2010","unstructured":"Yan, S. F., Ramasamy, R. & Schmidt, A. M. Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol 79, 1379\u20131386, https:\/\/doi.org\/10.1016\/j.bcp.2010.01.013 (2010).","journal-title":"Biochem Pharmacol"},{"key":"44608_CR23","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/s0002-9440(10)63909-0","volume":"162","author":"TM Wendt","year":"2003","unstructured":"Wendt, T. M. et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 162, 1123\u20131137, https:\/\/doi.org\/10.1016\/s0002-9440(10)63909-0 (2003).","journal-title":"Am J Pathol"},{"key":"44608_CR24","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1172\/jci17115","volume":"111","author":"T Sakaguchi","year":"2003","unstructured":"Sakaguchi, T. et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 111, 959\u2013972, https:\/\/doi.org\/10.1172\/jci17115 (2003).","journal-title":"J Clin Invest"},{"key":"44608_CR25","doi-asserted-by":"publisher","first-page":"R817","DOI":"10.1186\/ar1749","volume":"7","author":"R Pullerits","year":"2005","unstructured":"Pullerits, R., Bokarewa, M., Dahlberg, L. & Tarkowski, A. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther 7, R817\u2013824, https:\/\/doi.org\/10.1186\/ar1749 (2005).","journal-title":"Arthritis Res Ther"},{"key":"44608_CR26","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1161\/01.atv.0000160342.20342.00","volume":"25","author":"C Falcone","year":"2005","unstructured":"Falcone, C. et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 25, 1032\u20131037, https:\/\/doi.org\/10.1161\/01.atv.0000160342.20342.00 (2005).","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"44608_CR27","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1001\/archneur.62.11.1734","volume":"62","author":"E Emanuele","year":"2005","unstructured":"Emanuele, E. et al. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol 62, 1734\u20131736, https:\/\/doi.org\/10.1001\/archneur.62.11.1734 (2005).","journal-title":"Arch Neurol"},{"key":"44608_CR28","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/s0140-6736(05)67728-8","volume":"366","author":"BL Pihlstrom","year":"2005","unstructured":"Pihlstrom, B. L., Michalowicz, B. S. & Johnson, N. W. Periodontal diseases. Lancet 366, 1809\u20131820, https:\/\/doi.org\/10.1016\/s0140-6736(05)67728-8 (2005).","journal-title":"Lancet"},{"key":"44608_CR29","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1172\/jci8942","volume":"105","author":"E Lalla","year":"2000","unstructured":"Lalla, E. et al. Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest 105, 1117\u20131124, https:\/\/doi.org\/10.1172\/jci8942 (2000).","journal-title":"J Clin Invest"},{"key":"44608_CR30","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/nrendo.2011.74","volume":"7","author":"H Vlassara","year":"2011","unstructured":"Vlassara, H. & Striker, G. E. AGE restriction in diabetes mellitus: a paradigm shift. Nat Rev Endocrinol 7, 526\u2013539, https:\/\/doi.org\/10.1038\/nrendo.2011.74 (2011).","journal-title":"Nat Rev Endocrinol"},{"key":"44608_CR31","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1196\/annals.1433.055","volume":"1126","author":"H Vlassara","year":"2008","unstructured":"Vlassara, H., Uribarri, J., Cai, W. & Striker, G. Advanced glycation end product homeostasis: exogenous oxidants and innate defenses. Ann N Y Acad Sci 1126, 46\u201352, https:\/\/doi.org\/10.1196\/annals.1433.055 (2008).","journal-title":"Ann N Y Acad Sci"},{"key":"44608_CR32","doi-asserted-by":"publisher","first-page":"224","DOI":"10.5808\/gi.2013.11.4.224","volume":"11","author":"EJ Lee","year":"2013","unstructured":"Lee, E. J. & Park, J. H. Receptor for Advanced Glycation Endproducts (RAGE), Its Ligands, and Soluble RAGE: Potential Biomarkers for Diagnosis and Therapeutic Targets for Human Renal Diseases. Genomics Inform 11, 224\u2013229, https:\/\/doi.org\/10.5808\/gi.2013.11.4.224 (2013).","journal-title":"Genomics Inform"},{"key":"44608_CR33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.numecd.2008.03.004","volume":"19","author":"GD Norata","year":"2009","unstructured":"Norata, G. D. et al. Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist\/hip ratio in the general population. Nutr Metab Cardiovasc Dis 19, 129\u2013134, https:\/\/doi.org\/10.1016\/j.numecd.2008.03.004 (2009).","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"44608_CR34","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.05.037","volume":"23","author":"S Moriya","year":"2014","unstructured":"Moriya, S., Yamazaki, M., Murakami, H., Maruyama, K. & Uchiyama, S. Two soluble isoforms of receptors for advanced glycation end products (RAGE) in carotid atherosclerosis: the difference of soluble and endogenous secretory RAGE. J Stroke Cerebrovasc Dis 23, 2540\u20132546, https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2014.05.037 (2014).","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"44608_CR35","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1177\/1933719114549845","volume":"22","author":"M Pertynska-Marczewska","year":"2015","unstructured":"Pertynska-Marczewska, M. & Merhi, Z. Relationship of Advanced Glycation End Products With Cardiovascular Disease in Menopausal Women. Reprod Sci 22, 774\u2013782, https:\/\/doi.org\/10.1177\/1933719114549845 (2015).","journal-title":"Reprod Sci"},{"key":"44608_CR36","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/rheumatology\/kep079","volume":"48","author":"R Pullerits","year":"2009","unstructured":"Pullerits, R., d\u2019Elia, H. F., Tarkowski, A. & Carlsten, H. The decrease of soluble RAGE levels in rheumatoid arthritis patients following hormone replacement therapy is associated with increased bone mineral density and diminished bone\/cartilage turnover: a randomized controlled trial. Rheumatology (Oxford) 48, 785\u2013790, https:\/\/doi.org\/10.1093\/rheumatology\/kep079 (2009).","journal-title":"Rheumatology (Oxford)"},{"key":"44608_CR37","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.archoralbio.2012.06.007","volume":"57","author":"MM Abbass","year":"2012","unstructured":"Abbass, M. M., Korany, N. S., Salama, A. H., Dmytryk, J. J. & Safiejko-Mroczka, B. The relationship between receptor for advanced glycation end products expression and the severity of periodontal disease in the gingiva of diabetic and non diabetic periodontitis patients. Arch Oral Biol 57, 1342\u20131354, https:\/\/doi.org\/10.1016\/j.archoralbio.2012.06.007 (2012).","journal-title":"Arch Oral Biol"},{"key":"44608_CR38","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1600-051X.2004.00623.x","volume":"32","author":"J Katz","year":"2005","unstructured":"Katz, J. et al. Expression of the receptor of advanced glycation end products in gingival tissues of type 2 diabetes patients with chronic periodontal disease: a study utilizing immunohistochemistry and RT-PCR. J Clin Periodontol 32, 40\u201344, https:\/\/doi.org\/10.1111\/j.1600-051X.2004.00623.x (2005).","journal-title":"J Clin Periodontol"},{"key":"44608_CR39","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.2041-1626.2011.00079.x","volume":"2","author":"K Rajeev","year":"2011","unstructured":"Rajeev, K., Karthika, R., Mythili, R., Krishnan, V. & Nirmal, M. Role of receptors of advanced glycation end-products (RAGE) in type 2 diabetic and non-diabetic individuals with chronic periodontal disease: an immunohistochemical study. J Investig Clin Dent 2, 287\u2013292, https:\/\/doi.org\/10.1111\/j.2041-1626.2011.00079.x (2011).","journal-title":"J Investig Clin Dent"},{"key":"44608_CR40","doi-asserted-by":"publisher","unstructured":"Matsumoto, H. et al. The clinical significance of circulating soluble RAGE in patients with severe sepsis. J Trauma Acute Care Surg 78, 1086\u20131093; discussion 1093\u20131084, https:\/\/doi.org\/10.1097\/TA.0000000000000651 (2015).","DOI":"10.1097\/TA.0000000000000651"},{"key":"44608_CR41","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1475-2840-6-9","volume":"6","author":"PM Humpert","year":"2007","unstructured":"Humpert, P. M. et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 6, 9, https:\/\/doi.org\/10.1186\/1475-2840-6-9 (2007).","journal-title":"Cardiovasc Diabetol"},{"key":"44608_CR42","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3132\/dvdr.2008.031","volume":"5","author":"N Katakami","year":"2008","unstructured":"Katakami, N. et al. Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients. Diab Vasc Dis Res 5, 190\u2013197, https:\/\/doi.org\/10.3132\/dvdr.2008.031 (2008).","journal-title":"Diab Vasc Dis Res"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-44608-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-44608-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-44608-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T10:04:40Z","timestamp":1671271480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-44608-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,3]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["44608"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-44608-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,3]]},"assertion":[{"value":"15 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"8170"}}